Document Detail


The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
MedLine Citation:
PMID:  20452466     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Conventionnal therapy (moisturizers, pilocarpine, Cevimeline, local Cyclosporine, and hydroxychloroquine) remains the basis for the treatment of primary Sjögren's syndrome (pSS) but they do not modify the course of the disease. Rituximab is currently the most fully evaluated biologics in pSS. Open-label studies suggest that Rituximab is well tolerated (although infusion-related reactions and serum sickness remain possible), induces a rapid depletion of B cells in the blood and salivary glands, and could improve early active pSS or pSS with active extra glandular involvement. Two small double blind randomized studies have been conducted and now published, demonstrating its efficacy on fatigue and sicca syndrome in early disease. Two large double blind studies are currently ongoing or planned: The TEARS study (Tolerance and EfficAcy of Rituximab in primary Sjögren syndrome) in France, is currently including 120 patients having either a recent and active disease and/or at least one extraglandular severe signs. The 'TRACTISS' Study (Anti-B-Cell Therapy In Patients With Primary Sjögren's Syndrome), in UK, will include 100 patients having anti-Ro/La antibodies, reduced basal secretion but an increased salivary flow with stimulation, within 10years of diagnosis, symptomatic oral dryness, fatigue and at least one systemic feature.
Authors:
Alain Saraux
Related Documents :
6738376 - The oral ecology of patients with severe sjögren's syndrome.
18732436 - The sjogren-mikulicz syndrome-its relationship to connective tissue disorders.
25349926 - Polyarteritis nodosa complicated by posterior reversible encephalopathy syndrome: a cas...
9826056 - Ischemic choroidopathy in primary sjögren's syndrome.
7811426 - Hyperbrachycephaly, short face, midface hypoplasia, fusion of cervical vertebrae, radio...
15316976 - Giant omphalocele and "prune belly" sequence as components of the beckwith-wiedemann sy...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-05-07
Journal Detail:
Title:  Autoimmunity reviews     Volume:  9     ISSN:  1873-0183     ISO Abbreviation:  Autoimmun Rev     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-12     Completed Date:  2011-01-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101128967     Medline TA:  Autoimmun Rev     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  609-14     Citation Subset:  IM    
Affiliation:
EA2216, IFR148, Université de Bretagne Occidentale, Brest, and Service de Rhumatologie, Centre Hospitalier Universitaire de Brest, Brest, France. alain.saraux@chu-brest.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Murine-Derived / therapeutic use
B-Lymphocytes / drug effects,  immunology
Drug Delivery Systems
Humans
Randomized Controlled Trials as Topic
Sjogren's Syndrome / drug therapy*,  immunology
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Murine-Derived; 0/hLL2 agent; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  What do we know about memory B cells in primary Sjögren's syndrome?
Next Document:  Respiratory modulation of premotor cardiac vagal neurons in the brainstem.